Mineralys Therapeutics, Common Stock Probability of Future Stock Price Finishing Over 9.13
| MLYS Stock | 12.06 0.28 2.27% |
Mineralys |
Mineralys Therapeutics, Target Price Odds to finish over 9.13
The tendency of Mineralys Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above 9.13 in 90 days |
| 12.06 | 90 days | 9.13 | close to 99 |
Based on a normal probability distribution, the odds of Mineralys Therapeutics, to stay above 9.13 in 90 days from now is close to 99 (This Mineralys Therapeutics, Common probability density function shows the probability of Mineralys Stock to fall within a particular range of prices over 90 days) . Probability of Mineralys Therapeutics, price to stay between 9.13 and its current price of 12.06 at the end of the 90-day period is about 15.04 .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.11 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Mineralys Therapeutics, will likely underperform. Additionally Mineralys Therapeutics, Common has an alpha of 0.0509, implying that it can generate a 0.0509 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Mineralys Therapeutics, Price Density |
| Price |
Predictive Modules for Mineralys Therapeutics,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mineralys Therapeutics,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mineralys Therapeutics,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mineralys Therapeutics, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Mineralys Therapeutics, is not an exception. The market had few large corrections towards the Mineralys Therapeutics,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mineralys Therapeutics, Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mineralys Therapeutics, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 2.11 | |
σ | Overall volatility | 0.88 | |
Ir | Information ratio | 0.02 |
Mineralys Therapeutics, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mineralys Therapeutics, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mineralys Therapeutics, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mineralys Therapeutics, had very high historical volatility over the last 90 days | |
| Net Loss for the year was (71.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mineralys Therapeutics, generates negative cash flow from operations | |
| Mineralys Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 6349 shares by Rodman David Malcom of Mineralys Therapeutics, at 1.08 subject to Rule 16b-3 |
Mineralys Therapeutics, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Mineralys Stock often depends not only on the future outlook of the current and potential Mineralys Therapeutics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mineralys Therapeutics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.2 M | |
| Cash And Short Term Investments | 236.6 M | |
| Shares Float | 23.9 M |
Mineralys Therapeutics, Technical Analysis
Mineralys Therapeutics,'s future price can be derived by breaking down and analyzing its technical indicators over time. Mineralys Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Mineralys Therapeutics, Common. In general, you should focus on analyzing Mineralys Stock price patterns and their correlations with different microeconomic environments and drivers.
Mineralys Therapeutics, Predictive Forecast Models
Mineralys Therapeutics,'s time-series forecasting models is one of many Mineralys Therapeutics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Mineralys Therapeutics,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Mineralys Therapeutics,
Checking the ongoing alerts about Mineralys Therapeutics, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Mineralys Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Mineralys Therapeutics, had very high historical volatility over the last 90 days | |
| Net Loss for the year was (71.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mineralys Therapeutics, generates negative cash flow from operations | |
| Mineralys Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 6349 shares by Rodman David Malcom of Mineralys Therapeutics, at 1.08 subject to Rule 16b-3 |
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.